Use of A-192621 and IRL-2500 to Unmask the Mesenteric and Renal Vasodilator Role of Endothelin ETB Receptors
- 1 April 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 39 (4) , 533-543
- https://doi.org/10.1097/00005344-200204000-00009
Abstract
Endothelin-1 (ET-1) is known to cause a transient (1 h) pressor response. The former through the activation of ETB receptors, and the latter through the activation of ETA and ETB receptors. This study examines if ETB receptors mediate sustained mesenteric and renal dilation in anesthetized rats. Intravenous bolus ET-1 (0.8, 1.4, and 2 nmol/kg) and IRL-1620 (ETB agonist, 2, 5, and 10 nmol/kg) caused transient decrease followed by sustained increases in mean arterial pressure (MAP) that were accompanied by increases in total peripheral resistance (TPR), reductions in cardiac output (CO), and mesenteric and renal vasoconstriction. Pretreatment with FR-139317 (ETA antagonist, 1 mg/kg) attenuated the pressor and constrictor effects of ET-1 but did not alter responses to IRL-1620. IRL-2500 (ETB antagonist, 5 mg/kg) slightly inhibited the renal constrictor effect of IRL-1620, whereas A-192621 (ETB antagonist, 5 mg/kg) abolished all hemodynamic responses to IRL-1620. Both IRL-2500 and A-192621 markedly enhanced MAP, TPR, and mesenteric, and the renal constrictor effects of ET-1. Therefore, A-192621 was more effective than IRL-2500 in blocking IRL-1620–induced vasoconstriction, but both augmented constrictor responses to ET-1. The potentiation of ET-1–induced vasoconstriction by ETB receptor antagonists revealed a sustained vasodilator role of ETB receptors.Keywords
This publication has 42 references indexed in Scilit:
- Subtypes of endothelin receptors that mediate venous effects of endothelin‐1 in anaesthetized ratsBritish Journal of Pharmacology, 1997
- Effects of an ET1‐receptor antagonist, FR139317, on regional haemodynamic responses to endothelin‐1 and [Ala11,15]Ac‐endothelin‐1 (6–21) in conscious ratsBritish Journal of Pharmacology, 1994
- Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRFBritish Journal of Pharmacology, 1993
- Incomplete inhibition of endothelin-1 pressor effects by an endothelin ETA receptor antagonistEuropean Journal of Pharmacology, 1993
- Functionally Distinct Endothelin B Receptors in Vascular Endothelium and Smooth MuscleBiochemical and Biophysical Research Communications, 1993
- Incomplete inhibition of the pressor effects of endothelin‐1 and related peptides in the anaesthetized rat with BQ‐123 provides evidence for more than one vasoconstrictor receptorBritish Journal of Pharmacology, 1993
- Endothelin ETA and ETB receptors mediate vascular smooth muscle contractionBritish Journal of Pharmacology, 1992
- Endothelin-1 and Endothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and RabbitJournal of Cardiovascular Pharmacology, 1989
- Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.Proceedings of the National Academy of Sciences, 1988
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988